DURECT Corp (DRRX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:DURECT Corp (DRRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014199
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company’s product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect’s major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
DURECT Corp, Medical Devices Deals, 2011 to YTD 2017 9
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
DURECT Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Durect Enters into Licensing Agreement with Santen Pharma 11
Licensing Agreements 12
Sandoz Enters into Licensing Agreement with DURECT 12
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 13
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 15
Otonomy Enters into Licensing Agreement with Durect 16
DURECT Amends Licensing Agreement With Nycomed 17
Equity Offering 19
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 22
Durect Completes Public Offering Of Shares For US$11.5 Million 23
Durect Completes Public Offering Of Shares For US$13 Million 24
Asset Transactions 25
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp – Key Competitors 26
DURECT Corp – Key Employees 27
DURECT Corp – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 29
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 31
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 33
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 35
Oct 31, 2016: DURECT Announces Third Quarter 2016 Financial Results and Update of Programs 37
Aug 01, 2016: DURECT Announces Second Quarter 2016 Financial Results and Update of Programs 39
May 05, 2016: DURECT Announces First Quarter 2016 Financial Results and Update of Programs 41
Feb 29, 2016: DURECT Announces Fourth Quarter 2015 Financial Results and Update of Programs 43
Corporate Communications 45
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 45
Product News 46
04/07/2016: DURECT Announces POSIMIR Program Update 46
Clinical Trials 47
Jun 22, 2017: DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
DURECT Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Deals By Therapy Area, 2011 to YTD 2017 8
DURECT Corp, Medical Devices Deals, 2011 to YTD 2017 9
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Durect Enters into Licensing Agreement with Santen Pharma 11
Sandoz Enters into Licensing Agreement with DURECT 12
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 13
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 15
Otonomy Enters into Licensing Agreement with Durect 16
DURECT Amends Licensing Agreement With Nycomed 17
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 22
Durect Completes Public Offering Of Shares For US$11.5 Million 23
Durect Completes Public Offering Of Shares For US$13 Million 24
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp, Key Competitors 26
DURECT Corp, Key Employees 27

★海外企業調査レポート[DURECT Corp (DRRX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Allan Myers Inc:企業の戦略・SWOT・財務情報
    Allan Myers Inc - Strategy, SWOT and Corporate Finance Report Summary Allan Myers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fujitsu Australia Ltd:企業の戦略的SWOT分析
    Fujitsu Australia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mendor Oy-医療機器分野:企業M&A・提携分析
    Summary Mendor Oy (Mendor) is a medical equipment company that designs, develops and markets advanced diabetes management products. The company’s products include portable blood glucose meter and web-based software application for the daily management of diabetes. It offers blood glucose meter mendo …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Raytheon Co:企業のM&A・事業提携・投資動向
    Raytheon Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Raytheon Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Sibur Holding:企業の戦略的SWOT分析
    Sibur Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Edison SpA (EDNR):石油・ガス:M&Aディール及び事業提携情報
    Summary Edison SpA (Edison), a subsidiary of Electricite de France S.A., is an energy company that explores, produces, develops and sells natural gas and crude oil in the Mediterranean Basin. The company generates and sells electricity; and develops, stores, transports and sells gas in Italy. Edison …
  • Medicenna Therapeutics Corp (MDNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company. The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132. …
  • Allscripts Healthcare Solutions Inc (MDRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …
  • Aevi Genomic Medicine Inc (GNMX):製薬・医療:M&Aディール及び事業提携情報
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glut …
  • Filtration Group Corp:企業の戦略的SWOT分析
    Filtration Group Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Applebee’s Restaurants LLC:戦略・SWOT・企業財務分析
    Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report Summary Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Human Care HC AB:企業の戦略的SWOT分析
    Human Care HC AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • OTP Bank Nyrt:企業の戦略・SWOT・財務分析
    OTP Bank Nyrt - Strategy, SWOT and Corporate Finance Report Summary OTP Bank Nyrt - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Advanced Info Service Public Co Ltd (ADVANC):企業の財務・戦略的SWOT分析
    Advanced Info Service Public Co Ltd (ADVANC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • T2 Biosystems Inc (TTOO):医療機器:M&Aディール及び事業提携情報
    Summary T2 Biosystems Inc (T2 Biosystems) is a provider of clinical diagnostic products in the field of in vitro diagnostics. The company’s T2 magnetic resonance technology allows direct detection in complex samples such as whole blood, serum, plasma, sputum and urine. It offers T2HemoStat panel, T2 …
  • KSK Power Ventur plc (KSK):企業の財務・戦略的SWOT分析
    Summary KSK Power Ventur plc (KSK Power) is a power generation company that operates in development, operation, construction, and maintenance of power plants. The company operates through four business segments such as power generation, mineral resources, renewable and asset management, among others …
  • Cidara Therapeutics Inc (CDTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company's pipeline products include novel echinocandin CD101 IV, for the treatment of systemic candida in …
  • Neptune Technologies & Bioressources Inc:企業のM&A・事業提携・投資動向
    Neptune Technologies & Bioressources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Neptune Technologies & Bioressources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed …
  • Haworth Inc:企業の戦略的SWOT分析
    Haworth Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆